

27 January 2009
BioPharmica (ASX: BPH) ASX Announcement

Diagnostic Array Systems Complete Grant for the BacTrak™ System

The Diagnostic Array Systems (DAS) project BacTrak was given clinical funding in 2007 with the award of an AusIndustry Commercial Ready Grant. DAS has completed the term of the grant and met its objectives to develop BacTrak™ a diagnostic genetic microarray for the identification of microbial pathogens causing a range of lung diseases.

The grant in conjunction with BioPharmica funding has assisted in the development of BacTrak which includes a number of key features which underpin its commercial potential. These include:

- Rapid simultaneous detection of 16 respiratory pathogens including Tuberculosis (TB), Legionella and Methicillin resistant Staphylococcus Aureus (MRSA).
- Results within hours rather than days using the current culture gold standard.
- Sensitivity and positive confirmation for the 16 pathogens from easily obtained clinical sputum samples.
- Direct benefits from the project development include:
 - Earlier, appropriate treatment;
 - Shorter length of hospital stay;
 - Earlier potential isolation of hospital patients; and
 - Reduction in the over-prescription of broad-spectrum antibiotics

The ability of BacTrak to detect respiratory pathogens, including TB, Legionella and MRSA from a single sputum sample is of immense importance and potential value. Given the global significance and threat of TB in particular it is hoped large volume manufacturing by a suitable IVD manufacturer should deliver a low cost diagnostic kit suitable for deployment in both developing and third world countries.

BioPharmica is now actively marketing BacTrak with a view to identifying a strategic partner to deliver a commercial version of this unique diagnostic tool.

Diagnostic Array Systems holds intellectual property for the BacTrak technology in Australia, International patent filing is currently progressing through national phase in Canada, China, Europe, Japan and the United States (PCT/AU2006/001056).

Yours sincerely,



David Breeze
Chairman

For more information contact:

BioPharmica Limited
Tel : +61 8 9328 8366
<http://biopharmica.com.au>